Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
Summary
Appili’s portfolio addresses critical health challenges and has the potential to enhance national security, including: LIKMEZ™: An FDA-approved, taste-masked oral liquid suspension of the antibiotic metronidazole designed to treat bacterial infection. LIKMEZ is the first and only FDA-approved ready-made suspension of metronidazole for treating antimicrobial infections that addresses the unmet need in patients with dysphagia to avoid risks associated with drug compounding and discontinuation-related anti-microbial resistance. This novel topical formulation is developed to combat cutaneous leishmaniasis (CL), a devastating disease causing disfiguring skin lesions and affecting hundreds of thousands of people annually, primarily in tropical and subtropical regions. While PRVs can be traded, and recent transactions have averaged approximately US$100 million, their strategic value can extend beyond the secondary market, offering significant advantages in accelerating the development timeline of new treatments. Our shared vision and combined expertise will rapidly advance our mission to develop treatments for some of todays most critical national security risks.” Aditxt currently operates two programs focused on immune health and precision diagnostics.